German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies;Der Deutsche fibromyalgieverbraucherbericht. Nutzen und schaden von behandlungen des fibromyalgiesyndroms

Schmerz

Volumn 26, Issue 2, 2012, Pages 150-159

  Hauser W ^a,b   Jung, E ^a,b   Erbsloh Moller B ^c   Gesmann, M ^d   Kuhn Becker H ^d   Petermann, F ^e   Langhorst, J ^f   Weiss, T ^g   Thoma, R ^d   Winkelmann, A ^h  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Rheumatologische Praxis   (Germany)

^d Psychosomatische Medizin und Schmerztherapie ^*  (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

^f KLINIKEN ESSEN MITTE   (Germany)

^g Praxisklinik Dr Weiss   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Consumer reports; Drug therapy; Fibromyalgia syndrome; Risks and benefits; Self management

Indexed keywords

ADULT; AEROBIC EXERCISE; ARTICLE; CLINICAL PRACTICE; CONSUMER; EDUCATION; EUROPE; FEMALE; FIBROMYALGIA; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PHYSIOTHERAPY; PSYCHOTHERAPY; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; SELF CARE; SELF REPORT;

ADULT; AGED; ANALGESICS; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; FEMALE; FIBROMYALGIA; HUMANS; INTERDISCIPLINARY COMMUNICATION; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT CARE TEAM; PATIENT SATISFACTION; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REHABILITATION CENTERS; RISK ASSESSMENT;

EID: 84863664429     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-012-1161-5     Document Type: Article

References (22)

1. Bennett RM, Jones J, Turk DC et al (2007) An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 9:8:27
2. Bernardy K, Füber N, Köllner V, Häuser W (2010) Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 37:1991-2005
3. Choy E, Perrot S, Leon T et al (2010) A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res 26:102
4. Frost J, Okun S, Vaughan T et al (2011) Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from Patients Like-Me. J Med Internet Res 13:e6
5. Fuchs-Strizek R, Laireiter AR, Baumann U, Hessler E (2011) Retrospektives Katamnesedesign in der psychotherapeutischen Praxisforschung - Kriterien und Anwendung. Psychother Psychosom Med Psychol 61:262-268
6. Goldenberg DL (2009) Diagnosis and differential diagnosis of fibromyalgia. Am J Med 122(12 Suppl):14-21
7. Häuser W, Schiedermaier P (2005) Das Fibromyal-giesyndrom in der Sozialgerichtsbarkeit - psychosoziale Risikofaktoren und Prädiktoren der Inanspruchnahme medizinischer Leistungen. Psychother Psychosom Med Psychol 55:72-78 (Pubitemid 40278595)
8. Häuser W, Eich W, Herrmann M et al (2009) Klinische Leitlinie Fibromyalgiesyndrom. Klassifikation, Diagnose und Behandlungsstrategien. Dtsch Arztebl Int 106:383-391
9. Häuser W, Klose P, Langhorst J et al (2010) Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 12:R79
10. Häuser W, Schild S, Kosseva M et al (2010) Validierung der deutschen Version der regionalen Schmerzskala zur Diagnose des Fibromyalgiesyn-droms. Schmerz 24:226-235
11. Häuser W, Petzke F, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11:505-521
12. Häuser W, Biewer W, Gesmann M et al (2011) A comparison of the clinical features of fibromyalgia syndrome in different settings. Eur J Pain 15:936-941
13. Kroenke K Spitzer RL, Jannett BW et al (2009) An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 50:613-621
14. Langhorst J, Häuser W, Irnich D, Speeck N, Felde E, Winkelmann A, Lucius H, Michalsen A, Musial F (2008) Komplementäre und alternative Therapien beim Fibromyalgiesyndrom. Schmerz 22:324-333
15. Löwe B, Wahl I, Rose M et al (2010) A4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 122:86-95
16. Marschall U, Arnold B, Häuser W (2011) Behandlung und Krankheitskosten des Fibromyalgiesyn-droms in Deutschland - Eine Analyse der Daten der Barmer Ersatzkasse des Jahres 2008-2009. Schmerz 25:402-410
17. Müller A, Hartmann M, Eich W (2000) Health care utilization in patients with fibromyalgia syndrome (FMS). Schmerz 14:77-83 (Pubitemid 30256456)
18. Sanego. http://www.sanego.de/Krankheiten/Fib-romyalgie/. Zugegriffeb:6. Dezember 2011
19. Schiltenwolf M, Häuser W, Felde E et al (2008) Physiotherapie, medizinische Trainingstherapie und physikalische Therapie beim Fibromyalgiesyndrom. Schmerz 22:303-312
20. Seligman M (1995) The effectiveness of psychotherapy. The Consumers Reports Study. Am Psychol 50:965-974
21. Wolfe F, Clauw sDJ, Fitzcharles MA et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 38:1113-1122
22. Wolfe F, Häuser W, Hassett AL et al (2011) The development of fibromyalgia - I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 152:291-299